A
Allan Wissner
Researcher at American Cyanamid
Publications - 74
Citations - 4122
Allan Wissner is an academic researcher from American Cyanamid. The author has contributed to research in topics: Alkoxy group & Platelet-activating factor. The author has an hindex of 19, co-authored 74 publications receiving 3989 citations.
Papers
More filters
Journal ArticleDOI
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Kwak Eunice L,Raffaella Sordella,Daphne W. Bell,Godin-Heymann Nadia G,Ross A. Okimoto,Brian W. Brannigan,Patricia L. Harris,David R. Driscoll,Panos Fidias,Thomas J. Lynch,Sridhar K. Rabindran,John P. McGinnis,Allan Wissner,Sreenath V. Sharma,Kurt J. Isselbacher,Jeffrey Settleman,Daniel A. Haber +16 more
TL;DR: These findings suggest that one of these, HKI-272, may prove highly effective in the treatment of EGFR-mutant NSCLCs, including tumors that have become resistant to gefitinib or erlotinib.
Journal ArticleDOI
Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase
Sridhar K. Rabindran,Carolyn Discafani,Edward Rosfjord,Michelle Baxter,M. Brawner Floyd,Jonathan Golas,W. A. Hallett,Bernard Dean Johnson,Ramaswamy Nilakantan,Elsebe Overbeek,Marvin F Reich,Ru Shen,Xiaoqing Shi,Hwei-Ru Tsou,Yu-Fen Wang,Allan Wissner +15 more
TL;DR: HKI-272 is a potent inhibitor ofHER-2 and is highly active against HER-2-overexpressing human breast cancer cell lines in vitro and in vivo, and has been selected as a candidate for additional development as an antitumor agent in breast and other HER- 2-dependent cancers.
Journal ArticleDOI
Combinatorial chemoprevention of intestinal neoplasia.
Christopher J. Torrance,Peta E. Jackson,Peta E. Jackson,Elizabeth A. Montgomery,Kenneth W. Kinzler,Bert Vogelstein,Allan Wissner,Maria Tereza Nunes,Philip Frost,Carolyn Discafani +9 more
TL;DR: A combination of two drugs afforded remarkable protection from intestinal neoplasia in APCMin/+ mice, a murine model of human familial adenomatous polyposis, suggesting a powerful strategy for the chemoprevention of human colonic neopl Asia.
Journal ArticleDOI
Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino] propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent beta-adrenergic agonist virtually specific for beta 3 receptors. A promising antidiabetic and antiobesity agent.
Jonathan D. Bloom,Minu Dutia,Bernard Dean Johnson,Allan Wissner,Michael G. Burns,Elwood Largis,Jo Alene Dolan,Thomas H. Claus +7 more
Journal ArticleDOI
Synthesis and Structure−Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2)
Allan Wissner,Elsebe Overbeek,Marvin F Reich,M. Brawner Floyd,Bernard Dean Johnson,Nellie Mamuya,Edward Rosfjord,Carolyn Discafani,Rachel Davis,Xiaoqing Shi,Sridhar K. Rabindran,Brian C. Gruber,Fei Ye,W. A. Hallett,Ramaswamy Nilakantan,Ru Shen,Yu-Fen Wang,Lee M. Greenberger,Hwei-Ru Tsou +18 more
TL;DR: A series of of 6,7-disubstituted-4-anilinoquinoline-3-carbonitrile derivatives that function as irreversible inhibitors of EGFR and HER-2 kinases have been prepared and one compound, 5, which shows excellent oral in vivo activity, was selected for further studies and is currently in phase I clinical trials for the treatment of cancer.